Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …

Purpose: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple
malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits …

The antiangiogenic agent bevacizumab has been approved for the treatment of non–small
cell lung cancer (NSCLC), although the survival benefit associated with this agent is …

Itraconazole is an oral antifungal that has a been reported to have anticancer effect in non-
small cell lung cancer (NSCLC) through inhibition of angiogenesis. The aim is to evaluate …

In a recent window-of-opportunity study, we repurposed an established antifungal agent as
a potential cancer therapy [1]. Specifically, we administered itraconazole for 10–14 days to …

Introduction Preclinical studies have suggested that the oral antifungal agent itraconazole
specifically inhibits proliferation, migration, and tube formation of endothelial cells …

Understanding cancer biology and the development of novel agents for cancer treatment
has always been the goal of cancer researchers. However, the research and development of …

Background: Carboxyamidotriazole (CAI), a calcium channel blocker, inhibits tumor cell
proliferation, metastasis, and angiogenesis. This trial aimed to determine whether CAI …

Objective To report the case of a patient receiving itraconazole for the treatment of
histoplasmosis and his subsequent reduction in pancreatic tumor size. Case summary A 64 …

e13565 Background: Preclinical studies show that itraconazole (ITRA) has inhibitory activity
against human umbilical vein endothelial cells. It also decreases angiogenesis with 67.5 …